Eupraxia Pharmaceuticals Inc
EPRX5.960USD
-0.040-0.65%
종가 09/19, 16:00（ET）시세는 15분 지연됩니다
214.32M시가총액
손실P/E TTM
자세한 내용은 Eupraxia Pharmaceuticals Inc 회사
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
회사 정보
종목 코드 EPRX
회사 이름Eupraxia Pharmaceuticals Inc
상장일Mar 09, 2021
CEODr. James A. Helliwell, M.D.
직원 수33
유형Ordinary Share
회계 연도 종료Mar 09
주소201-2067 Cadboro Bay Rd.
도시VICTORIA
증권 거래소The Toronto Stock Exchange
국가Canada
우편 번호V8R 5G4
전화12505903968
웹사이트https://eupraxiapharma.com/home/default.aspx
종목 코드 EPRX
상장일Mar 09, 2021
CEODr. James A. Helliwell, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
224.87K
--
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
46.34K
+18.22%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
13.93K
--
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Joseph Freedman
Mr. Joseph Freedman
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Mr. Paul A. Brennan
Mr. Paul A. Brennan
Chief Business Officer
Chief Business Officer
--
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
224.87K
--
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
46.34K
+18.22%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
13.93K
--
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Joseph Freedman
Mr. Joseph Freedman
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Tue, Sep 9
마지막 업데이트: Tue, Sep 9
주주
주주 유형
주주
주주
비율
Disbrow (Robert)
8.04%
Freedman (Joseph S)
4.20%
Scotia Capital Inc.
3.59%
Montalbano (John S.)
3.37%
Helliwell (James Allen)
1.87%
기타
78.92%
주주
주주
비율
Disbrow (Robert)
8.04%
Freedman (Joseph S)
4.20%
Scotia Capital Inc.
3.59%
Montalbano (John S.)
3.37%
Helliwell (James Allen)
1.87%
기타
78.92%
주주 유형
주주
비율
Individual Investor
19.13%
Research Firm
3.83%
Investment Advisor
1.34%
Investment Advisor/Hedge Fund
0.10%
Hedge Fund
0.08%
기타
75.52%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
28
9.09M
25.29%
+3.21M
2025Q1
33
13.45M
37.66%
+9.00M
2024Q4
29
12.81M
35.95%
+8.38M
2024Q3
26
11.48M
34.74%
+5.59M
2024Q2
21
8.52M
26.42%
+4.35M
2024Q1
12
3.99M
17.06%
-637.88K
2023Q4
16
7.00M
38.32%
+2.38M
2023Q3
16
7.01M
38.38%
+2.38M
2023Q2
15
6.89M
39.05%
+2.27M
2023Q1
16
6.89M
40.01%
+2.40M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Disbrow (Robert)
2.89M
8.04%
+2.89M
--
Sep 30, 2024
Freedman (Joseph S)
1.51M
4.2%
+10.00K
+0.67%
Jun 18, 2025
Scotia Capital Inc.
1.55M
4.32%
+160.96K
+11.57%
Mar 31, 2025
Montalbano (John S.)
1.21M
3.37%
--
--
Apr 25, 2025
Helliwell (James Allen)
674.01K
1.87%
--
--
Apr 25, 2025
Geyer (Paul L)
340.35K
0.95%
--
--
Apr 25, 2025
Wilmink (Michael)
224.87K
0.63%
--
--
Apr 25, 2025
RBC Dominion Securities, Inc.
206.63K
0.57%
+59.68K
+40.62%
Mar 31, 2025
RBC Phillips, Hager & North Investment Counsel Inc.
136.20K
0.38%
--
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
34.50K
0.1%
--
--
Mar 31, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
